Who is the CEO of Delcath Systems, Inc?
Gerard Michel is the CEO of Delcath Systems, Inc.
What is Delcath Systems, Inc. known for?
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company that focuses on the treatment of primary and metastatic liver cancers. The company is particularly known for its proprietary product, Melphalan Hydrochloride for Injection, which is used in the treatment of various liver cancers, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and ocular melanoma.
What types of liver cancers does Delcath target with its treatments?
Delcath Systems, Inc. primarily targets several types of liver cancers, including hepatocellular carcinoma (the most common type of liver cancer), intrahepatic cholangiocarcinoma (a cancer that forms in the bile ducts within the liver), and ocular melanoma (a rare type of eye cancer that can metastasize to the liver). Their treatments are designed to deliver targeted therapy directly to the liver, minimizing systemic exposure and potential side effects.
How does Delcath's proprietary treatment work?
Delcath's proprietary treatment involves the use of Melphalan Hydrochloride for Injection, which is administered through a specialized delivery system. This system allows for high doses of the chemotherapy drug to be delivered directly to the liver while minimizing exposure to the rest of the body. This targeted approach aims to enhance the effectiveness of the treatment while reducing systemic side effects, making it a promising option for patients with liver cancers.
What industries does Delcath Systems, Inc. serve?
Delcath Systems, Inc. primarily serves the healthcare and pharmaceutical industries, focusing on oncology. The company collaborates with hospitals, cancer treatment centers, and research institutions to provide innovative solutions for the treatment of liver cancers. Their products are designed to improve patient outcomes and are part of ongoing research and development efforts in the field of oncology.
Is Delcath involved in any clinical trials?
Yes, Delcath Systems, Inc. is actively involved in clinical trials to evaluate the safety and efficacy of its products. The company conducts research to gather data on the effectiveness of its treatments for liver cancers and to explore new applications for its proprietary technologies. Patients interested in participating in clinical trials should consult with their healthcare providers for more information on eligibility and enrollment.
Where can I find more information about Delcath's products and services?
For more information about Delcath Systems, Inc., including details on their products, ongoing clinical trials, and company updates, you can visit their official website at http://www.delcath.com. The site provides comprehensive resources for healthcare professionals, patients, and investors, including product information, research publications, and news releases.
